Skip to content
MS
Sign in
unreviewed

Adenosine deaminase (ADA)

1 reactions · 1 pathways

Cofactors used

H2O

Clinical / pharmacological. ADA deficiency: severe combined immunodeficiency (dATP accumulation inhibits RNR)

What it does, reaction by reaction

1 reactions

Purine Degradation (to Uric Acid) Nucleotide Metabolism · Cytosol

step 3 Irreversible/directional

Adenosine → inosine

Converts Adenosine into Inosine

› Notes

Adenosine deaminase (ADA) catalyzes adenosine + H2O → inosine + NH3. The enzyme requires no external redox cofactor and channels adenosine toward hypoxanthine production.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Purine Degradation (to Uric Acid)

Listed there as: Adenosine deaminase

Accelerated by

Adenosine availability

Inhibited by

No major physiologic small-molecule allosteric inhibitor

Hormonal control

No established direct hormonal regulation.

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Closing the Surveillance-to-Stewardship Gap in antimicrobial resistance: a narrative review of global lessons from WHO GLASS, UK ESPAUR, and low- and middle-income countries.

    Elshenawy RA, Cernaliu A, Abe OM, Dsouza R, Chowdhury SM. · 2028-09-18

    unreviewed
  2. 2
    Directed biosynthesis of the designer peptidyl nucleoside antibiotics featuring a simplified azetidine-containing moiety.

    Gong R, Li T, Zhou L, Liu Y, Zhang T, Qin Y, Zeng X, Jin B, Wang J, Deng Z, Song X, Chen W. · 2026-09-08

    open access unreviewed
  3. 3
    Evaluation of Large Language Models in the Clinical Management of Patients With Upper Gastrointestinal Bleeding: Insights From Real-World Patient Data.

    Rajabnia M, Davoodi F, Hajisafarali M, Asadinia S, Shiri M, Shirzad F, Saeedi P, Mohammadi M. · 2026-07-09

    open access unreviewed
  4. 4
    Duplex detection of anti-drug antibodies achieved by a spectrally resolved bioluminescence platform.

    Sun R, Zhang X, Qian MG. · 2026-07-22

    unreviewed
  5. 5
    Multichannel SSA decomposition in a hybrid SSA-N-BEATS framework for complex time series forecasting.

    Pratama AA, Hendikawati P. · 2026-09-17

    open access unreviewed
  6. 6
    Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral center.

    Avenatti E, Sadhu A, Gullapelli R, Rao A, Pavuluri C, Nasir K, Kashyap SR. · 2026-07-14

    open access unreviewed
  7. 7
    Ferroptosis in major depressive disorder: Molecular mechanisms, cellular vulnerability, and therapeutic opportunities.

    Kong D, Duan R, Wang X, Wang X, Zhao J. · 2026-09-18

    open access unreviewed
  8. 8
    Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.

    Mahmood T, Myrtziou I, Kanakis I. · 2026-09-26

    open access unreviewed
  9. 9
    Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.

    Syed A, Akce M, Malla M. · 2026-09-26

    open access unreviewed
  10. 10
    Gut microbiota functional remodeling and butyrate depletion amplify anti-Ro/La antibody-driven type I interferon activation in neonatal lupus.

    Sun W, Li Y, Liu X, Yu S, Li W, Wang H, Geng H, Li L, Hu J, Huo J, Zhang W, Fu J, Jin X, Li H, Zhou X, Zhu X. · 2026-09-16

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.